Pfizer, Inc. · NYSE:PFE
Pfizer — 27th Annual J.P. Morgan Healthcare Conference 2009
26 slides from Pfizer's conference presentation, Jan 13, 2009
Slide 1: 2009 JP Morgan Conference
2009 JP Morgan Conference Martin Mackay President, PGRD January 13, 2009
Slide 2: Forward-Looking Statements
Forward-Looking Statements Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2007 Annual Report on Form
Slide 3: Martin Mackay, President, PGRD
Martin Mackay President, PGRD
Slide 4: PGRD's Five Strategic Elements
PGRD’s Five Strategic Elements 1 Aggressively Deliver the Phase 2 and Phase 3 Portfolio 2 Prioritize Our Portfolio to Deliver the Most Value 3 Become a Top-Tier Biotherapeutics Company 4 Dramatically Raise the Bar on Productivity 5 Pursue the Best External Science
Slide 5: 2008 Achievements
2008 Achievements Global Approvals Global Submissions Fesoterodine Overactive Bladder (US) Fablyn Osteoporosis Treatment (Europe) Maraviroc HIV Treatment in Lyrica Post Herpetic Neuralgia (Japan) Experienced Patients (Japan) Xalacom Glaucoma (Japan) Macugen Age-Related Macular Degeneration (Japan) M
Slide 6: 2008 Achievements
2008 Achievements Advanced to Phase 3 Business Development Dimebon Alzheimer’s Dementia Auxilium Xiaflex for Dupuytren’s Tanezumab OA Signs and Symptoms contracture and Peyronie’s Disease CP-751871 Non-Small Cell Lung Cancer Sigma-Tau Eurartesim for malaria Axitinib Pancreatic Cancer Medivation Dime
Slide 7: Innovating Our Model with Smaller, More Accountable Business Units
Innovating Our Model with Smaller, More Accountable Business Units Primary Specialty Established Emerging Animal Oncology Care Care Products Markets Health Research and Business Units Biotherapeutics & Bioinnovation Center Late-Stage Sales & Medical Development Marketing Manufacturing Customer Focus
Slide 8: Advancing Compounds in the Pipeline
Advancing Compounds in the Pipeline Pipeline as of Sept 30, 2008 Over 300 Phase 1 Phase 2 Phase 3 In Reg. Total Discovery 50 38 25 1 Projects 114 Goals (Announced March 2008) 15–20 Phase 3 starts in 2008 – 2009 24–28 Programs in Phase 3 by end of 2009 15–20 Submissions 2010 – 2012 On-Track to
Slide 9: Recent Disease Area Decisions
Recent Disease Area Decisions Disease Area Focus Disease Area Exits* Alzheimer’s Disease Anemia Diabetes Atherosclerosis/Hyperlipidemia Inflammation/Immunology Bone Health/Frailty Oncology Gastrointestinal Pain Heart Failure Psychosis Liver Fibrosis Asthma/COPD Muscle G
Slide 10: Biotherapeutics and Bioinnovation Center
Biotherapeutics and Bioinnovation Center Federation of Technology-aligned Research Units and Biologic-generating Companies San Francisco fabrus UCSF/QB3 Ambryx FivePrime Rinat Scripps Antibodies MGH San Diego Wint- CovX RTC Boston herix Peptides BBC RNAi RGo Isogenica Bend PRM* Stem Cells Research U
Slide 11: Biotherapeutics in the Pipeline
Biotherapeutics in the Pipeline Research Development Marketed 72 17 5 $1.2B Est. 2008 Revenues Diverse Portfolio 9 TAs (interferon beta-1a) (dalteparin sodium injection) 6 Modalities 53 MAbs 9 Vaccines
Slide 12: Today's Phase 3 Portfolio
Today’s Phase 3 Portfolio axitinib – Pancreatic Cancer esreboxetine – Fibromyalgia apixaban – VTE Prevention Zithromax/chloro – Malaria Thelin – Pulmonary Hypertension Dalbavancin – Skin & Skin NMEs Dimebon – Alzheimer’s Disease Structure Infections CP-751871 – Lung Cancer tanezuma
Slide 13: Rebuilding the Phase 3 Portfolio
Rebuilding the Phase 3 Portfolio Number of Phase 3 Programs 24–28 26 16 8 Jan '07 Mar '08 Dec '08 Dec '09 Analyst Day Actual Projected NMEs New Indications
Slide 14: Select Late Stage Candidates
Select Late Stage Candidates Tanezumab (NGF Antibody) Pain CP-690550 (JAK3 Inhibitor) Rheumatoid Arthritis Dimebon (MPTP Modulator) Alzheimer’s Disease CP-751871 (IGF1R Antibody) Lung Cancer Sutent (Multiple Tyrosine Kinase Inh) Breast Cancer
Slide 15: Tanezumab: Overview
Tanezumab: Overview Acquired as part of Rinat deal Heavy Humanized, IgG2 MAb Chain High specificity and affinity for NGF Fast to market strategy with Osteoarthritis (OA) NGF Clinical efficacy demonstrated in OA 5 minute I.V. administration Low projected dose < 10 mg once every 8 wks Li
Slide 16: Tanezumab: Walking Knee Pain
Tanezumab: Walking Knee Pain (Mean Change ± Standard Error) Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Mean Change from Baseline 0 Over Weeks 1–16 (SE) Change in VAS from Baseline -10 Placebo -15.5 (2.6) Tanezumab -32.1 (2.5)* LS Mean (SE), mm -20 10 µg/kg Tanezumab -36.0 (2.5)* -30 25 µg/kg Tanezu
Slide 17: CP-690550 (JAK-3): Overview
CP-690550 (JAK-3): Overview Small molecule discovered in Evidence of efficacy in multiple Groton Labs human diseases of immunological dysregulation Key Milestones RA, kidney allograft rejection, FIH – March 2002 and psoriasis, all have continuing Phase 2 programs POM – June 2004 Phase
Slide 18: CP-690550 (JAK-3): Positive Primary Efficacy Results
CP-690550 (JAK-3): Positive Primary Efficacy Results Phase 2 RA Studies 12 Weeks Plus Background MTX in 6 Weeks Monotherapy in Patients Patients with Inadequate Response Who Had Failed MTX or a Tnfi to a Stable Dose of MTX
Slide 19: Dimebon: Overview
Dimebon: Overview Co-development with Medivation, Inc. Dimebon primary mechanism of action Enhances mitochondrial function Other pathways may also contribute In development for AD (Phase 3) and Huntington’s disease (HD, Phase 2) Clinical efficacy demonstrated across 5 clinical endpoints
Slide 20: Dimebon: Affects Cognition in Mild-to-Moderate AD
Dimebon: Affects Cognition in Mild-to-Moderate AD Treatment p = 0.0077 p < 0.0001 p < 0.0001 p < 0.0001 Effect 2.0 4.0 5.9 6.9 –3.0 Mean Change From Baseline –2.0 Clinical –1.0 Improvement Score ADS-cog 0.0 1.0 2.0 3.0 4.0 5.0 Dimebon (n = 89) Clinical 6.0 Deterioration Placebo (n = 94) Baseline 12
Slide 21: CP-751871 (figitumumab): Overview
CP-751871 (figitumumab): Overview Anti-IGF-1R mAb discovered in Groton Labs Fully human, IgG2 MAb First-in-class opportunity in highly competitive arena First selective anti-IGF mAb to enter human trials First to generate published Phase 2 data First to start formal Ph3 trials in mid-200
Slide 22: CP-751871: Plus Chemotherapy in 1st Line NSCLC
CP-751871: Plus Chemotherapy in 1st Line NSCLC Responses in Bulky Squamous Tumors US Spain Italy October 2005 August 2007 November 2007 February 2006 October 2007 April 2008 Ref: Karp et al, ASCO 2008
Slide 23: Sutent: Potential New Indications Expected to Drive Value
Sutent: Potential New Indications Expected to Drive Value Colorectal es nu ve Non-Small Cell Lung Re Hepatocellular Carcinoma Breast Renal Cell Carcinoma & Gastrointestinal Stromal Tumor Time
Slide 24: Sutent: Breast Cancer
Sutent: Breast Cancer Clinical anti-tumor activity in breast cancer Demonstrated in Phase 2, single-agent study in heavily pre- treated, advanced disease (ASCO, 2005) Preclinical and clinical rationale to combine and improve treatment with chemotherapy – Example: Phase 1 combination docetaxel
Slide 25: Commitments
Commitments On Track to Meet our March 5, 2008 Commitments 15–20 Phase 3 starts by end of 2009 24–28 Phase 3 programs by end of 2009 15–20 Submissions by 2010–2012
Slide 26: Working Together to Progress Assets, Programs and Technologies
Working Together to Progress Assets, Programs and Technologies Areas of Interest Types of Relationships Alzheimer’s Infectious Disease Licensing Disease Ophthalmology Co-develop/Co-promote Diabetes Smoking Cessation Alliances Inflammation & Immunology Thrombosis Venture Investments Oncology Biothera
Pfizer — 27th Annual J.P. Morgan Healthcare Conference 2009 on 6ix